摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-amino-5-(4-bromophenyl)-1,3-dimethyl-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile

中文名称
——
中文别名
——
英文名称
7-amino-5-(4-bromophenyl)-1,3-dimethyl-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile
英文别名
7-amino-5-(4-bromophenyl)-1,3-dimethyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrano[2,3-d]pyrimidine-6-carbonitrile;7-amino-5-(4-bromophenyl)-2,3,4,5-tetrahydro-1,3-dimethyl-2,4-dioxo-1H-pyrano[2,3d]pyrimidine-6-carbonitrile;7-amino-5-(4-bromophenyl)-1,3-dimethyl-2,4-dioxo-5H-pyrano[2,3-d]pyrimidine-6-carbonitrile
7-amino-5-(4-bromophenyl)-1,3-dimethyl-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile化学式
CAS
——
化学式
C16H13BrN4O3
mdl
——
分子量
389.208
InChiKey
SDLPUANKKRNWQJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    24
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.19
  • 拓扑面积:
    99.7
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    7-amino-5-(4-bromophenyl)-1,3-dimethyl-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile碘苯二乙酸三乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 0.5h, 以94%的产率得到2-(4-bromophenyl)-5,7-dimethyl-4,6,8-trioxo-5,7-diazaspiro[2.5]octane-1,1-dicarbonitrile
    参考文献:
    名称:
    吡喃并吡唑和吡喃并嘧啶二酮和路易斯酸分子内环丙烷化的螺环丙烷与螺环丙基吡唑啉酮的(3 + 2)环加成反应
    摘要:
    首先在温和的反应条件下,使用碘基苯(PhIO)或碘代苯二乙酸酯(PIDA)/分子碘(I 2)的组合,对吡喃并吡唑和吡喃并嘧啶-二酮衍生物进行强大的分子内环丙烷化反应,获得螺环丙基吡唑并酮和巴比妥酸酯。通过路易斯酸催化的合成的螺-环丙基吡唑啉酮与苯基异硫氰酸酯和苯并三腈的高非对映选择性(3 + 2)环加成反应,还证实了功能和立体化学多样化的新型螺并吡唑啉酮稠合的2-亚氨基噻吩和螺并吡咯啉酮稠合的吡咯啉支架。
    DOI:
    10.1021/acs.joc.7b00089
  • 作为产物:
    描述:
    1,3-二甲基巴比妥酸2-[((4-溴苯基)亚甲基]丙二腈1,4-二氧六环 为溶剂, 反应 0.03h, 以78%的产率得到7-amino-5-(4-bromophenyl)-1,3-dimethyl-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile
    参考文献:
    名称:
    Zoorob, Hanafi H.; Elzahab, Mohamed Abou; Abdel-Mogib, Mamdouh, Arzneimittel-Forschung/Drug Research, 1997, vol. 47, # 8, p. 958 - 962
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Synthesis of functionalized chromene and spirochromenes using l -proline-melamine as highly efficient and recyclable homogeneous catalyst at room temperature
    作者:Sakkani Nagaraju、Banoth Paplal、Kota Sathish、Santanab Giri、Dhurke Kashinath
    DOI:10.1016/j.tetlet.2017.09.060
    日期:2017.11
    commercially cheap l-proline and melamine for the synthesis of chromenes and spirochromenes (spirooxindoles) via multicomponent reactions at room temperature. Systematic studies were conducted in order to achieve desired reactivity and recyclability of the catalyst using various α-amino acids and aromatic amines as donor-acceptor pairs. Among the screened combinations, l-proline and melamine (3:1 ratio;
    使用便宜的1-脯酸和三聚氰胺开发了一种有效且可循环使用的均相催化剂,用于在室温下通过多组分反应合成色烯和螺环色酮(螺并辛多烯)。为了使用各种α-氨基酸和芳族胺作为供体-受体对,进行系统研究以实现所需的反应性和催化剂的可回收性。在筛选的组合中,l脯酸和三聚氰胺(3:1的比例;占总重量的3 mol%)被认为是最佳的催化剂,可以在室温下非常短的时间内(1-15分钟)以优异的产率(高达99%)提供所需的产品在DMSO中作为溶剂。通过添加EtOAc来回收催化剂,并且在不损失催化活性的情况下重复使用多达5个循环。
  • Effect of Liquid Glass Composition on the Catalytic Preparation of Pyrano[2,3-d]pyrimidine Derivatives
    作者:Mehdi Abaszadeh、Seyyed Jalal Roudbaraki、Majid Ghashang
    DOI:10.1080/00304948.2019.1600124
    日期:2019.5.4
    compounds containing at least one core moiety of pyrano[2,3-d]pyrimidine have received considerable attention in synthetic organic chemistry because of their potential as drugs and bioactive compounds. Pyrano[2,3-d]pyrimidines have attracted interest in medicine as antitumor, anti-hypertensive, antibacterial and antileishmanial drugs. Pyrano[2,3-d]pyrimidines have been produced by a number of methods. A
    本研究的主要目的是使用液态玻璃作为催化剂催化制备5-芳基-1,3,4,5-四氢2H-吡喃并[2,3-d]嘧啶-6-腈衍生物。所有反应均在中回流条件下进行。作为进一步的目标,使用高速球磨 (HSBM) 技术研究了该过程。研究了液态玻璃成分和添加金属氧化物杂质的影响。最近,含有至少一个喃并[2,3-d]嘧啶核心部分的化合物因其作为药物和生物活性化合物的潜力而在合成有机化学中受到了相当大的关注。喃并[2,3-d]嘧啶作为抗肿瘤、抗高血压、抗菌和抗利什曼病药物在医学上引起了人们的兴趣。喃并[2,3-d]嘧啶已通过多种方法生产。可以获得对合成程序的完整审查和关于这些化合物的讨论。分子式为 Na2(SiO2)nO 的液态玻璃是一种硅酸溶液,可通过 NaOH (25%) 与 SiO2 反应或通过将碳酸二氧化硅熔化来制备。数十年来,液态玻璃一直被用作粘合剂和涂层剂。液态玻璃是一种无毒、耐热
  • The first urea-based ionic liquid-stabilized magnetic nanoparticles: an efficient catalyst for the synthesis of bis(indolyl)methanes and pyrano[2,3-<i>d</i>]pyrimidinone derivatives
    作者:Mohammad Ali Zolfigol、Roya Ayazi-Nasrabadi、Saeed Baghery
    DOI:10.1002/aoc.3428
    日期:2016.5
    of bis(indolyl)methane derivatives via the condensation reaction between 2‐methylindole and aldehydes at room temperature under solvent‐free conditions. Also, pyrano[2,3‐d]pyrimidinone derivatives were prepared in the presence of the nanomagnetic urea‐based catalyst by the one‐pot three‐component condensation reaction of 1,3‐dimethylbarbituric acid, aldehydes and malononitrile under solvent‐free conditions
    基于尿素离子液体稳定在二氧化硅包覆的Fe 3 O 4磁性纳米颗粒上,Fe 3 O 4 @SiO 2 @(CH 2)3-尿素-SO 3H / HCl}是碱土中一种无与伦比的,平滑释放的尿素肥料,并通过傅立叶变换红外光谱,可见光和能量分散的X射线光谱,X射线衍射,扫描和透射电子显微镜,原子能对其进行了全面表征。力显微镜和热重分析。纳米结构催化剂是一种新型,绿色,高效的催化剂,它通过2-甲基吲哚与醛在室温下在无溶剂条件下的缩合反应用于合成双(吲哚基)甲烷生物。另外,喃并[2,3- d] pyrimidinone衍生物是在纳米磁性基催化剂存在下,在60°C无溶剂条件下,通过1,3-二甲基巴比妥酸,醛和丙二腈的单锅三组分缩合反应制备的。据我们所知,这是首次合成在二氧化硅包覆的Fe 3 O 4磁性纳米粒子上稳定的离子液体的报告。因此,当前的工作可以在合理设计,合成和应用特定任务的基于肥料
  • L-Proline based ionic liquid: A highly efficient and homogenous catalyst for synthesis of 5-benzylidene-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione and pyrano[2,3-d] pyrimidine diones under ultrasonic irradiation
    作者:Paresh G. Patil、Yuvraj Satkar、Dhananjay H. More
    DOI:10.1080/00397911.2020.1811987
    日期:2020.12.16
    Abstract A catalytic, practical, efficient procedure for the synthesis of 5-benzylidene-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione and pyrano[2,3-d] pyrimidine diones at room temperature was developed using L-Proline nitrate ionic liquid under ultrasonic irradiation. The L-Proline nitrate is homogeneous and green catalyst easy to prepare by mixing L-Proline and nitric acid possess excellent catalytic
    摘要 一种在室温下催化合成 5-亚苄基-1,3-二甲基嘧啶-2,4,6(1H,3H,5H)-三酮和喃并[2,3-d]嘧啶二酮的实用高效方法是在超声辐照下使用 L-脯氨酸硝酸盐离子液体开发的。L-脯氨酸硝酸盐是由L-脯氨酸硝酸混合制备的均相绿色催化剂,在室温标准超声浴下对嘧啶核的合成具有优异的催化活性。这种充分的程序提供了一些优点,如使用绿色溶剂H2O,环境绿色良性程序,收率高,程序简单,反应时间短,不需要柱色谱分离和催化剂可重复用于五个后续反应。图形概要
  • SUBSTITUTED HETEROCYCLIC COMPOUNDS
    申请人:Abelman Matthew
    公开号:US20090012103A1
    公开(公告)日:2009-01-08
    The present invention relates to novel heterocyclic compounds and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I): wherein Q1, Q2, R2, R3, R4, R5, and R6 are as described herein. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.
    本发明涉及新颖的杂环化合物及其在治疗各种疾病状态中的应用,包括心血管疾病和糖尿病。在特定实施例中,化合物的结构由公式(I)给出:其中Q1、Q2、R2、R3、R4、R5和R6如本文所述。该发明还涉及制备这些化合物的方法,以及含有这些化合物的药物组合物。
查看更多

同类化合物

叔-丁基2-(甲磺酰)-5,7-二氢螺[吡喃并[4,3-D]嘧啶并-8,3-吡咯烷]-1-甲酸基酯 乙基7'-氨基-6-氟-2,2',4'-三羰基-1,1',2,2',3',4'-六氢螺[吲哚-3,5'-吡喃并[2,3-d]嘧啶]-6'-羧酸酯 7H-吡喃并[2,3-d]嘧啶-7-酮 7H-吡喃并[2,3-d]嘧啶 7,8-二氢-5H-吡喃并[4,3-D]嘧啶-2-胺 5H-吡喃并[4,3-d]嘧啶 5H-吡喃并[2,3-d]嘧啶 2H-吡喃并[2,3-d]嘧啶-6-甲腈,7-氨基-1,3,4,5-四氢-5-(4-甲氧苯基)-2,4-二羰基- 2,4-二氯-7,8-二氢-5H-吡喃[4,3-d]嘧啶 1H-吡喃并[3,4-d]嘧啶 1H-吡喃并[3,2-d]嘧啶 (5S,7R,8S)-2-methylsulfanyl-5,8-dihydro-7-allyloxymethyl-5-methoxy-pyrano[3,4-d]-pyrimidin-8-ol 5-ethyl-2-[(Z)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-ethyl-2-[[1-(3-methylbutanoyl)piperidin-4-ylidene]amino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-butyl-2-[(E)-1-(4-cyclohexylpiperazin-1-yl)butylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 2,3,3a,9-tetrahydro-5-iodo-2,3,3-trimethylimidazo[5,1-b][1,3]benzoxazin-1-one 2,4-dimethyl-9-methoxy-4,12b-dihydro-1H,7H-chromeno[4',3'-4,5]pyrano[2,3-d]pyrimidine-1,3(2H)-dione 5-methyl-3-{3-[(R)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-propyl}-1H-quinazoline-2,4-dione 7-amino-2-(benzothiazol-2-ylmethyl)-9-phenylthiazolo[4',5':6,5]pyrano[2,3-d]pyrimidine-8(7H)-one 2-[6-[(2-chlorophenyl)methyl]pyridin-2-yl]-7,8-dihydro-5H-pyrano[4,3-d]pyrimidine 8-amino-2-(methylthio)-5-oxo-6-(pyridin-4-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 5-(4-chlorophenyl)-1,3,8,8-tetramethyl-7,9-dihydro-5H-chromeno[2,3-d]pyrimidine-2,4,6-trione ethyl 7'-amino-2,4'-dioxo-2'-thioxo-1,1',2,2',3',4'-hexahydrospiroindole-3,5'-pyrano[2,3-d]pyrimidine-6'-carboxylate 8-amino-2-(methylthio)-5-oxo-6-(pyridin-3-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 7-Amino-4-oxo-5-phenyl-2-thioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carboxylic acid ethyl ester 3-(1H-benzoimidazol-2-yl)-3-butyl-5-methyl-dihydro-furan-2-one 3-(1H-benzoimidazol-2-yl)-3-(2-diethylamino-ethyl)-5-methyl-dihydro-furan-2-one 1-{4-[(1R,9S)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea (S)-6-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyridin-2(1H)-one 3-(1H-benzoimidazol-2-yl)-5-methyl-3-(3-methyl-butyl)-dihydro-furan-2-one 13-(3,4-dimethoxyphenyl)-5,5-dimethyl-2-thioxo-2,5,6,8,9,13-hexahydro-4H-pyrimido[5',4':6,7][1,8]naphthyridino[4,3,2-de]quinazoline-10,12(3a1H,11H)-dione (S)-3-allyl-8-ethyl-4,7-dioxo-2-(phenylcarbamoyl)-4,5,7,8-tetrahydro-3H-pyrano[4,3-d]pyrimidin-8-yl acetate 8-{[(2-bromo-3-methylphenyl)oxy]methyl}-1,3-dimethyl-2,3,4,6-tetrahydro-1H-pyrano[3,2-d]pyrimidine-2,4-dione 9-ethyl-6a-methyl-2-phenyl-8,9-dihydro-oxazolo[2,3-b]pyrimido[4,5-d][1,3]oxazin-5-one (S)-1-cyclobutyl-3-(4-(4-(3-methylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenyl)urea (S)-2-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyrimidin-4(3H)-one (6aRS,10aRS)-4,6,6a,7,8,9,10,10a-octahydro-2,4,6,6-tetramethyl-1H-<2>benzopyrano<3,4-d>pyrimidine-1,3(2H)-dione 5-ethyl-2-[(E)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione N3-(methyl 4-deoxy-α-L-threo-hex-4-enopyranosyluronate)-5-fluorouracil 1-{4-[(1S,9R)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea 4,5-dimethyl-12-(4-methoxyphenyl)-2-thioxo-2,4a,7,8,9,10,11,12-octahydrodipyrimido[4,5-b;4',5'-f] [1,8]naphthyridine-9,11-dione 2-[4-[2-hydroxyethyl(methyl)amino]-2-methyl-7-oxopyrimido[5,4-b][1,4]oxazin-8-yl]acetonitrile 5-ethyl-2-[(Z)-1-thiophen-2-ylethylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione